Browsing by Author "Díaz-Coronado, R"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Gliomas de alto grado en pacientes pediátricos post - radioterapia: reporte de dos casos en el Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
    (Universidad Peruana Cayetano Heredia, Facultad de Medicina Alberto Hurtado, 2022) Mego-Ramírez, FN; Casavilca-Zambrano, S; Negreiros-Chinchihuara, T; Cancino Maldonado, K; Ojeda-Medina, L; orrego-Puelles, JE; Díaz-Coronado, R
    Radiation therapy-induced high-degree gliomas (RIGs) are a rare complication with an ominous prognosis. Little is known about the underlying biology of RIGs, although some studies have suggested that there are no unique histologic or cytogenetic features to distinguish them from de novo glioblastomas. Two cases that meet the criteria to be considered RIG are reported, and pertinent pieces of literature are discussed. Two patients under 10 years of age, neither of whom had relevant genetic or clinical history, were diagnosed with primary cerebral gliomas at the National Institute of Neoplastic Diseases in Lima and, after radiation therapy cycles, developed high-degree secondary gliomas, confirmed in both patients by a histopathologic analysis. This report emphasizes the need to identify risk factors, molecular mechanisms of tumor development after radiotherapy, and probable therapeutic targets.
  • Thumbnail Image
    Publication
    Pediatric neuro-oncology in Latin America and the Caribbean: a gap to be filled
    (Frontiers Media S.A., 2024) Díaz-Coronado, R; Villar, RC; Cappellano, AM
    1 Childhood cancer and disease burden From the estimated 400,000children and adolescents who develop cancer each year, 80% live in low-middle income countries (LMIC) and are, unfortunately, responsible for 90% of the deaths in this age group (1, 2). The global outcome disparities are influenced by several factors mostly related to the availability of resources, with underprivileged patients placed “on the wrong side of a pediatric oncology ‘death canyon’”, with less than 5% of global resources for cancer dedicated to this group of patients (3–9).